Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptide inhibitor of endothelin converting enzyme

DOI Web Site Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 被引用文献3件 参考文献83件
  • Umekawa Kayo
    Discovery Research Laboratories I,Research Center,Sumitomo Pharmaceuticals Co.,Ltd.,Osaka 554-0022,Japan
  • Hasegawa Hirohiko
    Discovery Research Laboratories I,Research Center,Sumitomo Pharmaceuticals Co.,Ltd.,Osaka 554-0022,Japan
  • Tsutsumi Yasushi
    Discovery Research Laboratories I,Research Center,Sumitomo Pharmaceuticals Co.,Ltd.,Osaka 554-0022,Japan
  • Sato Kimihiko
    Discovery Research Laboratories I,Research Center,Sumitomo Pharmaceuticals Co.,Ltd.,Osaka 554-0022,Japan
  • Matsumura Yasuo
    Department of Pharmacology,Osaka University of Pharmaceutical Sciences,Osaka 569-1094,Japan
  • Ohashi Naohito
    Discovery Research Laboratories I,Research Center,Sumitomo Pharmaceuticals Co.,Ltd.,Osaka 554-0022,Japan

書誌事項

タイトル別名
  • Pharmacological Characterization of a Novel Sulfonylureid-Pyrazole Derivative, SM-19712, a Potent Nonpeptidic Inhibitor of Endothelin Converting Enzyme.

この論文をさがす

抄録

We describe the pharmacological characteristics of SM−19712 {4−chloro−N−[[(4−cyano−3−methyl−1−phenyl−1H−pyrazol−5−yl)amino]carbonyl]benzenesulfonamide, monosodium salt}.SM−19712 inhibited endothelin converting enzyme(ECE)solubilized from rat lung microsomes with an IC50 value of 42 nM and, at 10−100μM, had no effect on other metalloproteases such as neutral endopeptidase 24.11 and angiotensin converting enzyme, showing a high specificity for ECE.In cultured porcine aortic endothelial cells, SM−19712 at 1−100μM concentration−dependently inhibited the endogenous conversion of big endothelin−1(ET−1)to ET−1 with an IC50 value of 31μM.In anesthetized rats, either intravenous(1−30 mg/kg)or oral(10−30 mg/kg)administration of SM−19712 dose−dependently suppressed the pressor responses induced by big ET−1.In acute myocardial infarction of rabbits subjected to coronary occlusion and reperfusion, SM−19712 reduced the infarct size, the increase in serum concentration of ET−1 and the serum activity of creatinine phosphokinase.The present study demonstrates that SM−19712 is a structurally novel, nonpeptide, potent and selective inhibitor of ECE, and SM−19712 is a valuable new tool for elucidating the pathophysiological role of ECE.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 84 (1), 7-15, 2000

    公益社団法人 日本薬理学会

被引用文献 (3)*注記

もっと見る

参考文献 (83)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ